NASDAQ:MOR - MorphoSys Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $25.46
  • Forecasted Upside: 157.69 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$9.88
▲ +0.16 (1.65%)

This chart shows the closing price for MOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MorphoSys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MOR

Analyst Price Target is $25.46
▲ +157.69% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for MorphoSys in the last 3 months. The average price target is $25.46, with a high forecast of $59.00 and a low forecast of $12.00. The average price target represents a 157.69% upside from the last price of $9.88.

This chart shows the closing price for MOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 12 polled investment analysts is to hold stock in MorphoSys. This rating has held steady since April 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2021Morgan StanleyReiterated RatingOverweightLow
9/27/2021CitigroupDowngradeBuy ➝ NeutralLow
9/13/2021The Goldman Sachs GroupInitiated CoverageNeutral$12.00High
9/2/2021BarclaysReiterated RatingEqual WeightLow
8/5/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldHigh
8/4/2021Morgan StanleyReiterated RatingOverweightMedium
8/4/2021JPMorgan Chase & Co.Reiterated RatingNeutralMedium
7/27/2021SVB LeerinkReiterated RatingOutperform$13.50Medium
7/27/2021CommerzbankDowngradeBuy ➝ Hold$59.00High
7/10/2021Morgan StanleySet Price Target$18.80Low
7/9/2021Morgan StanleyReiterated RatingOverweightLow
6/16/2021Landesbank Baden-WuerttembergDowngradeBuy ➝ HoldLow
6/15/2021HSBCReiterated RatingHoldMedium
6/11/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$32.00 ➝ $24.00Low
6/3/2021Bryan, Garnier & CoDowngradeBuy ➝ NeutralMedium
6/3/2021SVB LeerinkUpgradeMarket Perform ➝ OutperformMedium
5/24/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$28.00High
5/21/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
4/8/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
3/29/2021Morgan StanleyReiterated RatingEqual WeightLow
3/23/2021SVB LeerinkReiterated RatingOutperform ➝ Market PerformLow
12/21/2020Berenberg BankReiterated RatingBuyLow
12/7/2020Smith Barney CitigroupReiterated RatingBuyHigh
11/25/2020Morgan StanleyInitiated CoverageEqual WeightMedium
11/18/2020The Goldman Sachs GroupInitiated CoverageNeutralMedium
11/13/2020BarclaysReiterated RatingEqual WeightN/A
10/2/2020BarclaysReiterated RatingEqual WeightN/A
8/10/2020CitigroupInitiated CoverageBuyN/A
6/25/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformN/A
5/13/2020BarclaysReiterated RatingEqual WeightN/A
5/12/2020HSBCUpgradeReduce ➝ HoldN/A
1/14/2020SVB LeerinkReiterated RatingOutperformHigh
11/27/2019GuggenheimInitiated CoverageBuyN/A
11/19/2019GuggenheimInitiated CoverageBuyN/A
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuyN/A
4/2/2019Berenberg BankUpgradeHold ➝ BuyN/A
1/11/2019SVB LeerinkReiterated RatingOutperformLow
12/10/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyN/A
11/14/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$32.00 ➝ $34.00N/A
11/5/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$38.00N/A
9/7/2018Berenberg BankDowngradeBuy ➝ HoldN/A
7/30/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldN/A
5/17/2018JPMorgan Chase & Co.Initiated CoverageOverweightN/A
5/14/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$38.00N/A
(Data available from 12/9/2016 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/12/2021
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/11/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2021
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/9/2021
  • 2 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 2 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

MorphoSys logo
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Read More

Today's Range

Now: $9.88
Low: $9.67
High: $9.89

50 Day Range

MA: $10.98
Low: $9.08
High: $12.45

52 Week Range

Now: $9.88
Low: $8.90
High: $30.75

Volume

139,434 shs

Average Volume

76,260 shs

Market Capitalization

$1.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of MorphoSys?

The following Wall Street sell-side analysts have issued reports on MorphoSys in the last twelve months: Barclays PLC, Berenberg Bank, Bryan, Garnier & Co, Citigroup Inc., Commerzbank AG, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, JPMorgan Chase & Co., Landesbank Baden-Wuerttemberg, Morgan Stanley, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for MOR.

What is the current price target for MorphoSys?

5 Wall Street analysts have set twelve-month price targets for MorphoSys in the last year. Their average twelve-month price target is $25.46, suggesting a possible upside of 157.7%. Commerzbank AG has the highest price target set, predicting MOR will reach $59.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $12.00 for MorphoSys in the next year.
View the latest price targets for MOR.

What is the current consensus analyst rating for MorphoSys?

MorphoSys currently has 9 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MOR, but not buy more shares or sell existing shares.
View the latest ratings for MOR.

How do I contact MorphoSys' investor relations team?

MorphoSys' physical mailing address is SEMMELWEISSTR. 7, PLANEGG 2M, 82152. The company's listed phone number is (498) 989-9270 and its investor relations email address is [email protected] The official website for MorphoSys is www.morphosys.com.